How Triomics Uses AI To Help Doctors Treat Cancer More Quickly

How Triomics Uses AI To Help Doctors Treat Cancer More Quickly

How Triomics Uses AI To Help Doctors Treat Cancer More Quickly

https://www.forbes.com/sites/davidprosser/2026/06/03/how-triomics-uses-ai-to-help-doctors-treat-cancer-more-quickly/

Publish Date: 2026-06-03 07:00:00

Source Domain: www.forbes.com

  • Doctors’ Information Overload: Clinicians face immense pressure to process extensive patient records, often spanning hundreds of pages, which hampers timely diagnosis and treatment for cancer patients.

  • Triomics’ AI Solution: Triomics, a New York-based tech startup, aims to alleviate this burden with its AI platform, created to reduce time spent on information processing and improve decision-making for oncologists.

  • Enhanced Efficiency: Triomics’ AI, based on specialized large language models, processes patient records efficiently, leading to a 67% reduction in chart review time and a 40% improvement in matching patients to clinical trials.

  • Rapid Expansion: Since its 2021 inception, Triomics has rapidly grown, now partnering with centers treating around 15% of American cancer patients, including leading cancer centers like Memorial Sloan Kettering and the Mount Sinai Tisch Cancer Center.

  • Focus on Accuracy and Transparency: The platform emphasizes accuracy and transparency by providing verifiable sources for its outputs and ensuring doctors can meet compliance needs, rather than relying on implicit trust in AI.

  • Revenue and Growth: Triomics’ revenue is in seven figures, and the company plans to expand its audit and reporting services, supported by a £22 million Series B funding round, surpassing $36 million in total funding.

  • Strategic Investment: The Series B funding, led by Battery Ventures, includes participation from Nexus Venture Partners, Lightspeed, Y Combinator, and specialists from oncology and health informatics providing strategic support.

  • Future Plans: The company intends to scale through recruiting engineering and clinical experts while further improving its AI models and expanding its services.